EGFR and neoplasm: Patients with RAS mutations have been described to suffer from a more aggressive course of disease, including faster tumour growth, higher likelihood of metastasis and poorer overall survival and disease-free survival rates [33], due to resistance to specific targeted therapies (anti-Epidermal Growth Factor Receptor therapies) [34, 35].